



ATC codes: **L01XA01**

Indication	Squamous cell carcinoma of oropharynx <span>ICD11 code: <b>2C3A.0</b></span>
INN	Cisplatin
Medicine type	Chemical agent
List type	Complementary
Formulations	Parenteral > General injections > IV: 50 mg per 50 mL ; 100 mg per 100 mL
EML status history	First added in 1984 ( <a href="#">TRS 722</a> ) Changed in 2015 ( <a href="#">TRS 994</a> )
Sex	All
Age	Adolescents and adults
Therapeutic equivalence	The recommendation is for this specific medicine
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 

Tags

Cancer

Wikipedia

[Cisplatin](#) 

DrugBank

[Cisplatin](#) 

### Summary of evidence and Expert Committee recommendations

Cisplatin was originally added to the EML in 1984. In 2009, cisplatin was replaced by carboplatin with a square box for treatment of advanced ovarian cancer. In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, cisplatin was added to the complementary list of the EML for use as a radio-sensitizer in treatment protocols for head and neck cancer. The relevant extract from TRS994 regarding the Expert Committee's consideration of treatment protocols for early and advanced stage head and neck cancers is attached.

[Expert Committee report](#) 

